Quick Answer
Matinas BioPharma Holdings, Inc. reported Net Income of -$10.35 million for fiscal year 2025.
Matinas BioPharma Holdings, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$10.35M | +57.3% |
| 2024 | -$24.25M | -5.7% |
| 2023 | -$22.94M | -9.3% |
| 2022 | -$21.00M | +9.8% |
| 2021 | -$23.28M | -3.7% |
| 2020 | -$22.45M | -29.2% |
| 2019 | -$17.37M | -23.4% |
| 2018 | -$14.08M | +9.1% |
| 2017 | -$15.49M | -103.8% |
| 2016 | -$7.60M | +16.8% |
| 2015 | -$9.14M | +10.6% |
| 2014 | -$10.22M | -175.3% |
| 2013 | -$3.71M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.53M | +64.2% | +70.8% |
| June 30, 2025 | -$5.25M | +8.3% | -216.7% |
| March 31, 2025 | -$1.66M | +71.6% | +61.3% |
| September 30, 2024 | -$4.28M | +29.4% | +25.2% |
| June 30, 2024 | -$5.72M | +5.6% | +1.8% |
| March 31, 2024 | -$5.82M | -5.6% | +3.8% |
| September 30, 2023 | -$6.05M | -10.9% | +0.1% |
| June 30, 2023 | -$6.06M | -2.3% | -9.9% |
- Matinas BioPharma Holdings, Inc. showed an increase of +57.3% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, Matinas BioPharma Holdings, Inc.’s net income has declined by 178.6% (from -$3.71 million to -$10.35 million).
- The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: